Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
Apr 25 ASND Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
Apr 25 LLY 20 Fastest Growing Health Tech Companies in the World
Apr 25 UTHR Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
Apr 25 LQDA Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
Apr 25 LLY Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics
Apr 25 LLY Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Apr 25 RVPH RVPH: Full Year 2023 Results
Apr 24 CNTA Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point
Apr 24 LLY Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
Apr 24 UTHR Doctors perform first combined heart pump and pig kidney transplant surgery
Apr 24 LLY 4 Large Drug Stocks to Hold on to Amid Industry Challenges
Apr 24 LLY Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Apr 24 UTHR United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
Apr 24 LLY Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Apr 24 UTHR United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Apr 24 ASND United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
Apr 24 UTHR United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
Apr 24 LLY Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Apr 24 LQDA When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable?
Apr 24 CNTA Centessa Pharmaceuticals prices $100M ADS offering
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags